Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself

• Status: Withdrawn
• Trial end date: 2007-12-04

Summary

The purpose of this study is to demonstrate that Visudyne-Lucentis-dexamethasone (V-L-D) triple therapy will give similar efficacy and safety results as Lucentis monotherapy.

• Phase: Phase 2

Details

• Lead Sponsor: Vitreous -Retina- Macula Consultants of New York
• Collaborator: QLT Inc.
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Ranibizumab; Verteporfin